A Review of Vancomycin Population Pharmacokinetic Studies in Adult Critically Ill Patient by Setiawan, Eko & Montakantikul, Preecha
HS-30-OF 
82 
 
A Review of Vancomycin Population Pharmacokinetic 
Studies in Adult Critically Ill Patient 
Eko Setiawan 
Clinical Pharmacy Division ( Department of Pharmacy 
Faculty of Pharmacy ( Mahidol University 
Bangkok, Thailand 
 
Centre for Medicine Information and Pharmaceutical Care 
Faculty of Pharmacy ( University of Surabaya 
Surabaya Indonesia 
 
Preecha Montakantikul  
Clinical Pharmacy Division ( Department of Pharmacy 
Faculty of Pharmacy ( Mahidol University 
Bangkok, Thailand 
 
 
 
Abstract  Background E fficacy of vancomycin, the most 
recommended anti!M RSA antibiotics, was best represented 
with A U C24/M I C>400 which was greatly determined by 
pharmacokinetic (P K) and pharmacodynamics parameters. 
G iving a standard dose of vancomycin to any populations with 
deviated pharmacokinetic parameters, as found in the critically 
ill population, will impact on the achievement of A U C24 and 
M I C coverage. Objective This review was conducted to 
investigate the profile of critically ill adult P K  parameters and 
examine the effects of the different P K   parameters to the 
achievement of A U C24 and maximum M I C coverage. Method 
L iterature search was conducted using PubMed and T rip 
Database from the database inception to July 2012. Published 
articles which present the critically ill population P K  equation 
model will be included in the review . Reference case analysis 
will be used to calculate the P K  parameters, A U C24, and 
maximum M I C coverage. Result There were 5 critically ill 
adult population P K  studies met the inclusion criteria. E ach 
study shows specific P K  equation model for Vd and C L . Only 4 
studies were included in the reference case analysis. Result 
from reference case analysis for the Vd and C L were: 69L , 
58.8L , 104.04L , 49.2L ; and 4.29L/h, 5.12L/h, 3.586L/h, 3.19L/h , 
consecutively. The A U C24 (in mg.hr .L-1) and maximum M I C of 
M RSA strain (in mg/L) that still could be covered by giving 
standard dose of vancomycin were: 466.2, 390.63, 557.72, 
626.96; and 1.16, 0.98, 1.39, 1.56. While, the Vd, C L , A U C24, 
and maximum M I C of M RSA resulted from general population 
equation model calculation were 37.2L , 2.6L/h, 769.23mg.hr .L-1, 
and 1.92mg/L . Conclusion G iving standard dose of vancomycin 
to the critically ill population yielded a lower achievement of 
total A U C24 leading to lower M I C of M RSA strain that stil l 
could be covered. C lose monitoring and dose adjustment, if 
needed, should be given to ensure the achievement of desi red 
target treatment.   
Keywordsvancomycin; population pharmacokinetic study; 
critically ill  
I. INTRODUCTION  
Methicillin-resistant Staphylococcus aureus (MRSA) is a 
common pathogen found in the hospital setting [1-4]. 
Compared with the methicillin-susceptible strain, infection 
caused by MRSA usually result in higher mortality rate [5-7]. 
There are several independent mortality risk factors for 
patient who are infected with MRSA, and one of the most 
prominent risk factors is an intensive care unit (ICU) 
admitted [8]. Severe condition is not the only reason for 
higher mortality found in this setting. Inappropriate used for 
antimicrobial treatment, either empirical and definite 
antibiotic therapy, also plays as a major determinant factor in 
the final !! + "! [8-15]. Inappropriate used with 
antibiotics  +! limiting only to the erroneous choice of 
antibiotics but also the failure to achieve target treatment. 
Vancomycin has long been used as the gold-standard in 
the management of MRSA infection. Nowadays, there is a 
great interest of using vancomycin to treat MRSA infection 
due to higher rates of treatment failure, especially in the case 
of infection caused by higher vancomycin minimum 
inhibitory concentration (MIC) MRSA strain, even still in the 
range of susceptibility breakpoint as classified by the Clinical 
and Laboratory Standards Institute (CLSI), i.e: <2mg/L [16-
23]. Further analysis found that patients who achieved area 
under the plasma drug concentration and time curve for 
24h/minimum inhibitory concentration (AUC24/MIC) >400 
had a higher percentage of clinical success compared with 
!  $ +! # ! 24,25]. Therefore, this 
pharmacokinetic-pharmacodynamic (PK-PD) index has been 
used as the target treatment of vancomycin in MRSA 
infection. This desired target treatment will totally depend on 
the AUC for 24h, which were greatly determined by the 
pharmacokinetic (PK) parameter of patients, and the 
distribution of MIC data.  
Critically ill population is one populated with the deviated 
physiologic condition compared with the general population. 
The different physiological condition leading to the 
differences in PK parameter profile [26-30]. The most 
affected PK parameters in this population are volume of 
distribution (Vd) and clearance (CL) that might impact on 
vancomycin blood concentration [28,29,31]. Lower blood 
concentration over time for 24h will result in lower AUC24, 
and as the consequences, without any appropriate dose 
adjustment, the higher MIC strain might not be covered. 
Infection that not treated with adequate AUC24 is classified as 
inappropriate used of antibiotics. As already mentioned 
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above, this practice will put the patients to the higher risk of 
treatment failure. 
Not many studies reported the exact figure of PK 
parameters in critically ill population. Rapidly changing of 
physiologic conditions found among this population makes 
valuing PK parameters even more complex. One of the most 
proposed methods in valuing PK parameters is population PK 
study. The population PK study defined as quantitative 
assessment of typical PK parameters, and the between-
individual and residual variability in drug absorption, 
distribution, metabolism, and excretion [32]. The advantage 
by using this method is the ability to identify the source of 
variability in the PK parameters for certain populations. 
Population PK study presents an equation model for certain 
PK parameters, yij 	'ij.j, xij-ij, where yij is observed data 
that is intended to identify, 'ij is a specified function for 
predicting, -ij is the measurement of   .j is  an 
individual true parameter. From this equation model, it is 
shown that variability exists among individual in the 
population will not be ignored and, therefore, will result a 
prediction as close as the real condition. The equation model 
was established by adding a factor that known to influence 
the PK parameters one by one to the certain basic equation 
model. Factor that giving significantly contributed to the 
equation model will be retained in the final equation model. 
Studies have shown single value of PK parameters, without 
using any equation model in calculation, usually ignore the 
variability exist between individual  ! +!
classify as population PK study. This study aims to 
investigate the population PK studies conducted in the 
critically ill adult patients and examine the effects of different 
PK parameter profile to the achievement of AUC24 and 
maximum MIC value of MRSA whether it can be covered by 
giving a standard dose of vancomycin. Reference case 
analysis, using the specific characteristic of the patient, will 
be used to calculate the PK parameter, AUC24 and maximum 
MIC coverage. 
II. MATERIALS AND METHOD 
A. Definition 
Critically ill patient in this study is defined as a patient 
with acute impairs in one or more vital  organ systems such 
that there is a high probability of imminent or life 
threatening deterioration in the !!+  condition [33]. By 
this definition, critically ill patient will not only limited 
implied to those who are admitted in the ICU department. 
Septic, trauma, post-surgical, burn and cancer patients are 
usually classified in this population [26-28]. Patient with age 
&7 year old are considered as an adult patient. One gram of 
vancomycin every 12h considered as a standard dose of 
vancomycin. Variables in the population PK study mean any 
factors that influence the values of PK parameters. 
B. Literature search 
PubMed and Trip Database were used to identify all 
vancomycin population PK studies conducted in the 
critically ill adult patients. A literature search was conducted 
from the database inception in July 2012 using several 
search terms, including: )vancomycin* 
 )"!
!  !"%*  )!% *  )"!
pharmacokinetic*)%*)*)"*
) "!*  ) "*  ) !- "* or 
)! #"!*. Follow-up of reference lists of relevant 
articles also has been done to an extent the searching method 
of the original article. 
 
C . Study selection 
All population PK studies conducted in adult critically ill 
patients published in English language will be included in this 
review. A study that included non-critically ill population or 
child population in the establishment of the population PK 
equation model, in vitro modelling, non-renal elimination 
modelling, and study just reported the pharmacokinetic 
parameters or +! clearly present the pharmacokinetic 
equation model will be excluded from the review. In order to 
be included in the reference case analysis, the study should 
clearly present the value of all variables used in the equation 
model. 
D . Reference-case 
Sixty year old male patient, weight 60kg, height 160cm, 
with normal serum creatinine 0.8mg/dL will be used as a 
reference case, either for critically ill population and general 
population, to calculate PK parameters for each population 
PK equation model. After derived PK parameters, AUC24 
will be calculated and then used to analyse maximum MIC 
value of MRSA strain that still can be covered by using 
standard dose of vancomycin. Pharmacokinetic parameters, 
AUC24, and maximum MIC value calculated from equation 
model of critically ill population will be compared with ones 
of general population. 
Pharmacokinetic parameters for critically ill population 
will be calculated using each equation model derived from 
studies found in the literature search. While, for general 
population will be calculated using equations listed below. 
The first PK parameter should be calculated was Ke [34]. 
Ke = (0.00083 x CLcr) + 0.0044               (1) 
Ke stands for elimination rate constant (h-1); and CLcr stands 
for creatinine clearance (mL/min). 
Creatinine clearance (CLcr) will be calculated using 
Cockcroft and Gault+  equation [35,36]. This equation also 
used for CLcr calculation in the critically ill population 
equation model. 
CLcr = [(140-age) weight] / (72 x Scr)              (2) 
Age (year); weight used in this equation should be ideal 
body weight (IBW; in kg); Scr stands for serum creatinine 
(mg/dL) [35,36].  
 
IBW = 50kg + (2.3kg) each inch of height over 5 feet       (3) 
To convert height from cm to inch, this equation will be 
used: 
Height in cm/2.54                             (4) 
The second PK parameter should be calculated was Vd [34]. 
                             Vd = 0.62L/kg x TBW                           (5) 
Vd stands for volume distribution (L). 
The third PK parameter, clearance of vancomycin, was 
calculated by multiplying the first and second PK parameters 
[34-36]. 
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CL = Ke x Vd                                     (6) 
CL stands for vancomycin clearance (L/h). 
After getting clearance for vancomycin, then AUC24 can be 
calculated by using [37]: 
AUC24 = total daily dose of vancomycin/CL          (7) 
 
Maximum MIC of MRSA strain that can still be covered, 
will be calculated by using the following equation:  
          Maximum MIC of MRSA strain = AUC24/400         (8) 
 
III. RESULTS 
A total of 74 studies was identified during the literature 
search. And finally there were 21 adults critically ill 
population studies retrieved for more detailed evaluation and 
only 5 studies met the inclusion criteria. Details of the study 
flow presented in the figure 1. Most studies used intermittent 
infusion of vancomycin with the mean dose between 
1,000mg-1,500mg. Dose adjustment was usually conducted 
   ! !!+   "! Number of blood 
concentration sampling at least 3 per patient in these studies. 
Only study conducted by Robert, et al, used continuous 
infusion  +!  the number of sampling per 
patient.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Study review flowchart 
Population PK studies  
There were 5 population PK equation models derived 
from different critically ill populations, including: post 
Cardiothoracic surgery patients (n=1), hematological 
malignancy patients (n=1), all ICU patients (n=3) [38-42]. 
Complete population PK equation models were presented in 
! !  !"  !! +!  ! ! peripheral Vd 
means that they used one-compartment model in their 
analysis. Symbol  used in the equation model represented 
the estimate for PK parameter. The objective function value 
(OFV) was used in all studies as a criteria whether certain 
variable should be retained in the final equation model or 
should be rejected. In the first process, where the basic 
equation model was added with variable one by one, the 
OFV difference between basic equation model and added 
variable equation model should be at least 3.84 (with degree 
of freedom = 1). And for the second process, a backwards 
elimination process where each variable was fixed to zero 
value, the OFV difference should be at least 6.63. Each 
model also reported interindividual and residual variability.  
 
Reference case analysis 
Four critically ill population studies were used in the 
reference case analysis [38-41]. Even though present the 
population PK equation model, study conducted by Robert, et 
al, did not show the value of  (both 1 and 2) in the 
equation model.  They just reported the final estimation of 
each pharmacokinetic parameter. Therefore, this study was 
not included in the reference case analysis. Table II presented 
the Vd and CL of vancomycin in critically ill population as 
well as AUC24 calculation and maximum MIC still can be 
covered by giving a standard dose of vancomycin. 
TABLE I.  CRITICALLY ILL POPULATION PK MODEL 
Author Population 
Population PK Model 
Peripheral 
Vd  Central Vd 
a Clearance 
Staatz, 
et al 
[38] 
Unstable 
renal 
function 
following 
cardio-
thoraxic 
surgery 
- 
1.15L/kg 
Inter-
individual 
variability 
36% 
 
1 x [(1+2) 
x (CLcr-
57)] 
Inter-
individual 
variability: 
27% 
1 = 2.94 
(estimation 
error 3%) 
2 = 0.0209 
(estimation 
error 3%) 
Residual variability: 15% 
Buelga, 
et al 
[39] 
Haemato-
logical 
malignancy 
-  
2x TBW 
Inter- 
individual 
variability: 
37.15% 
2 = 0.98 
(estimation 
error 7.43%) 
1 x CLcr 
Inter- 
individual 
variability: 
28.16% 
1 = 1.08 
(estimation 
error 
2.12%) 
Residual variability: 
3.52% 
!
51 studies potentially eligible 
to be included 
21 studies retrieved for more 
detailed evaluation 
Exclusion irrelevant studies (n=30): 
 Conducted in children or neonate (n=12) 
 No population PK equation model (n=7) 
 Utilization of PK parameters in the dosing 
normogram or individual dosing 
determination(n=11) 
16 studies excluded: 
 Semimechanistic in vitro model 
(n=3) 
 Include non-critically ill 
population or subject with <17 
year old for equation model 
building (n=11) 
 Lung penetration modelling (n=1) 
 Hepar function modelling (n=1) 
5 studies met inclusion criteria 
74 studies identified during 
literature search 
Exclusion irrelevant title (n=23) 
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Author Population 
Population PK Model 
Peripheral 
Vd  Central Vd 
a Clearance 
Llopis-
Salvia, 
et al 
[40] 
ICU 
patients 
5 x TBW 
Inter- 
individual 
variability: 
39.8% 
 
5 = 1.32 
(95%CI 
0.785-
1.855) 
 
 
3 x TBW 
Inter- 
individual 
variability: 
36.4% 
 
3 = 0.414 
(95%CI 
0.356-0.471) 
 
 
(1 x 
CLcr)+ (2 
x TBW) 
Inter- 
individual 
variability: 
29.2% 
 
1 = 0.034 
(95%CI 
0.01-0.056) 
2 = 0.015 
(95% -
0.001 ( 
0.039) 
 
Residual variability: 23.9% and 18.5% 
Revilla, 
et al 
[41] 
ICU 
patients -  
3 x 4A 
A=0 or 1 if 
Serum 
Creatinine1 
or >1mg/dL 
Inter- 
individual 
variability: 
22.83% 
 
3 = 0.82 
(95%CI 
0.94-0.70) 
4 = 2.49 
(95%CI 
2.98-2.00) 
 
1 x Clcr + 
Age2 
Inter- 
individual 
variability: 
30.13% 
 
1 = 0.67 
(95%CI 
0.76-0.58) 
2 = -0.24 
(95%CI -
0.21 ( -
0.27) 
Residual variability: 
4.23% 
Roberts, 
et al 
[42] 
ICU 
patients - 
1 x TBW 
Inter- 
individual 
variability: 
37.4% 
2 x Clcr 
Inter- 
individual 
variability: 
38.9% 
 
Residual variability: 
19.9% 
a. In case, no Vd peripheral presented in the model,Vd = Vd total 
     CLcr = creatinine clearance; TBW = total body weight 
TABLE II.  REFERENCE CASE ANALYSIS 
 
Author Population 
Parameters 
Vd (L) CL (L/h) 
AUC24 
(mg.hr/L) 
Max 
MIC 
(mg/L) 
Staatz, et al 
[38] 
Unstable renal 
function 
following 
cardiothoraxic 
surgery 
 
69 4.29 466.2 
 
 
1.16 
Buelga, et al 
[39] 
 
Haematological 
malignancy 58.8 5,12 390.63 0.98 
Llopis-Salvia, 
et al [40] ICU patients 
104.0
4 3.586 557.72 1.39 
Revilla, et al 
[41] 
 
ICU patients 49.2 3.19 626.96 1.56 
General 
population 
 
General 
population 37.2 2.60 769.23 1.92 
 
IV. DISCUSSION 
This review was focused on the population PK study of 
adult critically ill population with specific objectives to 
analyze the effect of deviated PK parameters found in this 
population to the achievement of AUC24 and maximum MIC 
coverage by giving a standard dose of vancomycin. There 
was another just published review of vancomycin population 
PK study conducted by Marsot, et al [43]. They reported all 
population PK studies both in adult and pediatric populations, 
but +!%ze the effect of different PK parameter to the 
achievement of AUC24 and MIC coverage by giving a certain 
dose of vancomycin. Finding from current review was in 
accordance with the finding from a study by Marsot, et al, i.e: 
Vd and CL were the most intended PK parameter to be 
modeled. Our review presents the creatinine clearance (CLcr) 
and body weight as an important variable for CL of 
vancomycin and Vd equation model, which just the same 
with what Marsot, et al presented in their review. 
Vancomycin was well characterized as a hydrophyllic 
drug with high molecular weight and was eliminated mainly 
by glomerular filtration [31,44]. By these characteristics, 
vancomycin will mostly distribute into the intravascular and 
interstitial space rather than further penetrate to the 
intracellular compartment. Two-compartment PK model was 
the best model describing PK process of vancomycin in the 
human body. Any condition changing the Vd and CL will 
greatly impact on vancomycin blood concentration profile. 
Since, AUC24 is calculated as a total of area under the plasma 
vancomycin concentration against time curve for 24h, any 
changes in blood concentration will impact on the total 
AUC24. Reference case calculation in table II has showed the 
same pattern of PK parameters in critically ill patients, i.e: 
higher Vd and faster CL compared with general population. 
There are some mechanisms might contribute to the higher 
Vd among critically ill patient, including endothelial 
dysfunction leading to the increase of capillary permeability 
and fluid shift to the interstitial space, hypoalbuminaemia 
which would lowered the intravascular oncotic pressure 
leading to fluid shift to the interstitial space, aggresive fluid 
treatment used to overcome some symptoms, using special 
medical services like mechanical ventilation or extracorporeal 
membrane oxigenase, and post-surgical drainages [26-30]. 
While, some mechanisms that increase the CL of vancomycin 
usually associated with enhancement of renal blood flow. 
Any process increasing the renal blood flow will increase the 
CL of vancomycin, such as increase cardiac output found in 
the early phase of sepsis as a natural compensation 
mechanism of the human body, and using haemodynamically 
active drugs (HAD) like dopamine to manage some 
symptoms. In the other hand, any condition that decreased the 
renal function will also decrease the clearance of 
vancomycin, as can be seen in patients who developed 
complication or those in severe condition [26-30]. 
Giving a standard dose of vancomycin to general 
population can cover higher MIC of MRSA strain compared 
with the critically ill population. As shown in the table II, 
almost all MRSA strains classified as susceptible by CLSI 
guideline can be covered by giving a standard dose of 
vancomycin [23]. While in critically ill population, different 
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figures of maximum MIC of MRSA strain that still could be 
covered by a standard dose of vancomycin were found. The 
lowest figure of MIC coverage was 0.98mg/L derived from a 
study conducted by Buelga, et al, and the highest was 
1.56mg/L derived from Revilla, et al. The value of AUC24 
ultimately is a determinant factor in this difference, where in 
Revilla, et al study, the AUC24 approximately two fold higher 
than Buelga, et al. Calculation of AUC24 in this review using 
an equation that assumed the steady state condition already 
achieved, therefore CL of vancomycin will determine the 
achievement of AUC24. Both equation models of CL 
vancomycin included CLcr as a variable with or without other 
variables. Since we use reference case analysis with the same 
CLcr for both equation models, there should be other factors 
contributing to the different CL of vancomycin. The values of 
1 in both equations were different, i.e: 0.67 in Revilla, et al 
and 1.08 in Buelga, et al. This difference plays as a major 
determinant in the total CL, since the additional variable 
included in Revilla, et al, i.e. age, just contribute 
approximately 0.7% from total CL. Different value of 1 
might be caused by different baseline characteristics of the 
patients included in both studies. All critically ill equation 
model included CLcr as a variable in their models.  
Body weight was the most influencing factor for Vd 
equation model. Equation model proposed by Revilla, et al, 
was the only Vd model that +!"!%$! 
covariate. They found no significant improvement of 
goodness-of-fit plots when included weight in the final Vd 
equation model. The equation model proposed by Llopis-
Salvia, et al, showed the highest Vd compared with another 
model. Higher Vd in this equation model correlated with two-
compartment PK model applied in this study, while another 
model using one-compartment PK model. In two-
compartment PK model, the Vd presented as a total Vd of 
peripheral and central compartments. In this equation model, 
peripheral compartment takes a major portion (75.85%) of  
total Vd. 
! +!"! !  ! !!
Vd. In study with main objective to determining the most 
appropriate loading or empirical dose, the impact of using 
different compartment PK model should be carefully 
considered.  
 We realize that the studies found in this review might be 
not all published population PK studies available, since only 
two database used and no any effort to search grey literature. 
   +! % " !!!  the fluctuation of 
physiologic condition occured in this population when we 
conducted the reference case analysis. However, due to the 
same pattern of PK parameters derived from accesable 
studies, result of this study emphasized the importance of 
close monitoring when prescribed standard dose of 
vancomycin to the critically ill patients, not only the 
achievement of recommended blood concentration but also 
vancomycin MIC of the MRSA strain. Especially in the era 
with increasing number of studies present the new 
phenomenon of shifting of vancomycin MIC of MRSA strain 
to the higher number even still classified as susceptible strain 
based on CLSI breakpoint recommendation [45-48]. The 
higher MIC value should be compensated with higher value 
of AUC24 to ensure the achievement of AUC24/MIC>400. 
Moreover, vancomycin dose adjustment might be needed to 
achieve higher AUC24 in this fluctuative PK profile 
population.  
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